{"id":"W2749380187","doi":"10.1056/nejmoa1709118","title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2412,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Daiichi Sankyo Europe; LEO Pharma; Servier; Novo Nordisk; Astellas Pharma; Fresenius Medical Care North America; Eisai; Belvoir Media Group; Ironwood Pharmaceuticals, Incorporated; Agence Nationale de la Recherche; Regado Biosciences; AstraZeneca; Amarin Corporation; Boston Scientific Corporation; Massachusetts Medical Society; Regeneron Pharmaceuticals; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; University College London; Bayer HealthCare; Sanofi; GlaxoSmithKline; Amgen; Pfizer; U.S. Department of Veterans Affairs","keywords":"Rivaroxaban; Aspirin; Medicine; Disease; Internal medicine; Cardiology; Intensive care medicine; Atrial fibrillation; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08434367790045115,"score_gpt":0.3424579357591593,"score_spread":0.2581142578587081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}